A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).
Polatuzumab vedotin in untreated DLBCL: one step forward, two steps back The manufacturer has designed its study for both the approval and Health Technology Assessments (HTA). However, the analyses ...